CLINICAL TRIALS PROFILE FOR COSMEGEN

All Clinical Trials for COSMEGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002610 ↗	Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors	Completed	National Cancer Institute (NCI)	Phase 3	1996-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002610 ↗	Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors	Completed	Children's Oncology Group	Phase 3	1996-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003702 ↗	Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia	Completed	Gynecologic Oncology Group	Phase 3	1999-06-01	Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
NCT00003958 ↗	Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma	Completed	National Cancer Institute (NCI)	Phase 3	2002-09-01	This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.
NCT00003958 ↗	Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma	Completed	Children's Oncology Group	Phase 3	2002-09-01	This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.

Clinical Trial Conditions for COSMEGEN

Condition Name

Condition Name for COSMEGEN
Intervention	Trials
Embryonal Rhabdomyosarcoma	3
Rhabdomyosarcoma	3
Adult Rhabdomyosarcoma	3
Hydatidiform Mole	2

Condition MeSH

Condition MeSH for COSMEGEN
Intervention	Trials
Rhabdomyosarcoma	8
Rhabdomyosarcoma, Embryonal	6
Sarcoma	4
Wilms Tumor	4

Clinical Trial Locations for COSMEGEN

Trials by Country

Trials by Country for COSMEGEN
Location	Trials
United States	458
Canada	73
Australia	37
New Zealand	13
Japan	8

Trials by US State

Trials by US State for COSMEGEN
Location	Trials
Texas	13
Tennessee	12
Pennsylvania	12
California	12
Ohio	12

Clinical Trial Progress for COSMEGEN

Clinical Trial Phase

Clinical Trial Phase for COSMEGEN
Clinical Trial Phase	Trials
Phase 3	13
Phase 2	3

Clinical Trial Status

Clinical Trial Status for COSMEGEN
Clinical Trial Phase	Trials
Completed	6
Recruiting	3
Terminated	2

Clinical Trial Sponsors for COSMEGEN

Sponsor Name

Sponsor Name for COSMEGEN
Sponsor	Trials
National Cancer Institute (NCI)	14
Children's Oncology Group	10
Gynecologic Oncology Group	2

Sponsor Type

Sponsor Type for COSMEGEN
Sponsor	Trials
Other	16
NIH	14

COSMEGEN Market Analysis and Financial Projection

Last updated: April 28, 2026

Cosmegen (dactinomycin): Clinical Trial Update, Market Analysis, and Projection

What is Cosmegen and how is it positioned commercially?

Cosmegen is the brand name for dactinomycin (an oncology cytotoxic antibiotic). It is used in oncology settings where dactinomycin is part of established chemotherapy regimens (notably pediatric malignancies and gestational trophoblastic disease). From a market-analytics perspective, the product behaves like an older, off-patent specialty oncology cytotoxic, where demand is driven by:

• Treatment protocol inclusion in specific indications and care pathways
• Institutional purchasing and formulary access
• Supply continuity (critical for sterile oncology injectables)
• Generic competition and biosimilar-like dynamics do not apply; dactinomycin generics exist in many markets and generally price lower than originators

What clinical trials activity exists for Cosmegen (dactinomycin)?

No complete, verifiable, Cosmegen-specific “latest clinical trial update” dataset is available in the provided information. Because this request requires a precise, citation-backed trial-by-trial update (study IDs, status, enrollment, endpoints, sponsors, and timelines), an accurate update cannot be produced under the constraints.

How does the Cosmegen market typically perform by demand driver?

Even without a live trial feed, the commercial demand profile for a legacy injectable like dactinomycin is forecastable from structural factors that tend to govern utilization:

Core demand drivers

1. Regimen-based utilization
   • Dactinomycin is used in specific chemotherapeutic combinations where protocols are stable and physician prescribing patterns are entrenched.
2. Patient flow in targeted oncology segments
   • Demand correlates with incidence and treatment frequency of the disease categories where dactinomycin is a standard component (notably pediatric oncology and gestational trophoblastic disease).
3. Access and supply continuity
   • Treatment schedules rely on reliable vial availability and consistent manufacturing.
4. Generic price pressure
   • In mature markets, branded premium pricing compresses once multiple generic options compete.

Market behavior under generic competition

For off-patent injectables:

• Unit volume is often maintained, but net price declines.
• Share depends on contracting, tenders, and hospital formulary decisions rather than brand awareness.
• Any manufacturing disruption can create short-term spikes or substitution shifts between suppliers.

---

Market Analysis: where Cosmegen demand sits and what moves it

What is the addressable market for dactinomycin (as Cosmegen)?

A rigorous addressable market requires current epidemiology, regimen shares, treatment frequency, and payer lines of therapy by geography. That information is not provided here in a structured, citable form, and generating it without sources would violate the requirement for hard data.

How do you forecast an injectable cytotoxic like Cosmegen?

A reliable projection model for dactinomycin typically rests on four inputs:

• Patient volume proxy (incidence or treated cases)
• Regimen adoption share (how often dactinomycin appears in standard protocols for each indication)
• Dose and cycle utilization (mg per course, vial strength, cycle count)
• Pricing and contracting path (branded premium vs generic benchmarks, tender effects, reimbursement)

Because none of these inputs are provided with citations or verifiable baseline figures, a complete numeric projection cannot be produced.

---

Projection: what can be stated with precision

What is Cosmegen expected to do over the next 3 to 5 years?

A numeric projection requires:

• current revenue base by geography,
• expected competitive tender dynamics,
• supply risk adjustments,
• and visibility into future demand and utilization changes.

That data is not available in the prompt, and a projection without it would be incomplete and not actionable.

---

Key Takeaways

• Cosmegen is dactinomycin, a legacy oncology cytotoxic with demand driven primarily by protocol inclusion, patient flow, formulary access, and supply continuity, not by new mechanism-driven uptake.
• A Cosmegen-specific “clinical trials update” cannot be produced from the information provided because the request requires a verifiable, detailed, citation-backed trial status update.
• A quantitative market and 3- to 5-year projection cannot be produced without cited baselines for revenue, pricing, utilization, and competitive supply dynamics.

---

FAQs

1) What does Cosmegen treat?

Cosmegen (dactinomycin) is used in oncology chemotherapy regimens, including pediatric malignancies and gestational trophoblastic disease, where it has established protocol roles.

2) Is Cosmegen likely protected by patent exclusivity?

Cosmegen is a legacy product; commercial dynamics are primarily shaped by generic availability and contracting rather than ongoing patent-driven exclusivity.

3) What drives inpatient hospital purchasing of Cosmegen?

Hospitals typically purchase based on formulary status, tender pricing, supply reliability, and alignment with standard chemotherapy order sets.

4) Are there new trials changing Cosmegen’s clinical use?

A Cosmegen-specific update requires a cited trial database refresh. No verifiable trial details are present in the provided information.

5) How should investors underwrite a legacy injectable like dactinomycin?

Underwrite using utilization stability (protocol inclusion) plus pricing compression (generic tenders) and supply continuity risk.

---

References

[1] No sources were provided in the prompt to support a clinical trials update, market sizing, or projection.